Thromb Haemost 1999; 82(04): 1359-1360
DOI: 10.1055/s-0037-1614391
Letters to the Editor
Schattauer GmbH

Abnormally High Frequency of Inherited Pro-thrombotic Conditions in Subjects with Recurrence of Venous Thrombosis

Umberto Piemontino
1   From the Centro di Riferimento Regionale per le Emocoagulopatie, Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Napoli “Federico II”, Napoli, Italy
,
Giovanna Guiotto
1   From the Centro di Riferimento Regionale per le Emocoagulopatie, Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Napoli “Federico II”, Napoli, Italy
,
Francesco Rugiada
1   From the Centro di Riferimento Regionale per le Emocoagulopatie, Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Napoli “Federico II”, Napoli, Italy
,
Ferdinando Cirillo
1   From the Centro di Riferimento Regionale per le Emocoagulopatie, Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Napoli “Federico II”, Napoli, Italy
,
Anna Maria Cerbone
1   From the Centro di Riferimento Regionale per le Emocoagulopatie, Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Napoli “Federico II”, Napoli, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 13. April 1999

Accepted after major revision 16. Juni 1999

Publikationsdatum:
08. Dezember 2017 (online)

 

 
  • References

  • 1 Prandoni P, Lensing AWA, Cogo A. et al. The long term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
  • 2 Kniffin WD, Baron JA, Barret J, Birkmeyer JD, Anderson Jr FA. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154: 861-6.
  • 3 Hirsh J. The optimal duration of anticoagulation therapy for venous thromboembolism. N Engl J Med 1995; 332: 1710-1.
  • 4 Schulman S, Granqvist S, Holmstrom M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
  • 5 Diuguid DL. Oral anticoagulant therapy for venous thromboembolism. N Engl J Med 1997; 336: 433-4.
  • 6 Bertina RM, Koeleman BPC, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
  • 7 Ridker PM, Hennekens CH, Lindpaintner K. et al. Mutation in the gene coding fo coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
  • 8 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosi. Arterioscl Thromb Vasc Biol 1999; 19: 700-3.
  • 9 Margaglione M, Brancaccio V, Giuliani N. et al. Increased risk of venous thrombosis in carriers of the prothrombin A20210 gene variant. Ann Intern Med 1998; 129: 89-93.
  • 10 Ridker PM, Miletich JP, Stampfer MJ. et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
  • 11 Simioni P, Prandoni P, Lensing AWA. et al. The risk of recurrent venous thromboembolism in patients with an Arg506 → Gln mutation in the gene for factor V (factor V leiden). N Engl J Med 1997; 336: 399-403.
  • 12 Eichinger S, Pabinger I, Stumpflen A. et al The risk of recurrent venous thromboembolism in patient with and wihout factor V Leiden. Thromb Haemost 1997; 77: 624-8.